Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Meghan Donnelly
CONTACT
James Robinson
CONTACT
Lead
Children's Hospital of Philadelphia
With
This is an open label, non-randomized study to evaluate the efficacy and safety of the combination of larotrectinib followed by 131I therapy for patients with NTRK fusion differentiated thyroid cancer. The primary Phase II objective will be to evaluate the pulmonary structural response rate at 18 months to the combination of larotrectinib given for 6-months followed by 131I therapy.
Age
2–99
Sex
ALL
Healthy volunteers
Not accepted